166 related articles for article (PubMed ID: 12530261)
1. [Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV
Vopr Onkol; 2002; 48(6):668-72. PubMed ID: 12530261
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV
Vopr Onkol; 2003; 49(1):66-70. PubMed ID: 12715373
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
4. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
5. [Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV
Vopr Onkol; 2004; 50(6):726-8. PubMed ID: 15755073
[TBL] [Abstract][Full Text] [Related]
6. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
7. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
8. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
9. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
10. Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Linch DC; Yung L; Smith P; Maclennan K; Jack A; Hancock B; Cunningham D; Hoskin P; Qian W; Holte H; Boesen AM; Grigg A; Browett P; Trneny M
Br J Haematol; 2010 Apr; 149(2):237-43. PubMed ID: 20201949
[TBL] [Abstract][Full Text] [Related]
11. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
12. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Fetscher S; Lübbert M; Kanz L; Behringer D; Finke J; Mertelsmann R; Lange W
Bone Marrow Transplant; 1997 Mar; 19(5):527-8. PubMed ID: 9052926
[TBL] [Abstract][Full Text] [Related]
14. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
[TBL] [Abstract][Full Text] [Related]
15. [Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease].
Uss AL; Zmachinskiĭ VA; Milanovich NF; Skriagin AE; Dziuba EV; Vlasenkova SV; Solov'eva NS; Batan ZE; Mitskevich PB; Zavgorodniaia IL; Aleĭnikova OV; Zhavrid EA
Vopr Onkol; 2000; 46(5):619-23. PubMed ID: 11202200
[TBL] [Abstract][Full Text] [Related]
16. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
[TBL] [Abstract][Full Text] [Related]
17. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
[TBL] [Abstract][Full Text] [Related]
18. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
20. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]